Esperion Therapeutics Inc (NASDAQ:ESPR) has a beta value of 0.84 and has seen 1.54 million shares traded in the recent trading session. The company, currently valued at $287.87M, closed the recent trade at $1.46 per share which meant it lost -$0.04 on the day or -3.00% during that session. The ESPR stock price is -169.86% off its 52-week high price of $3.94 and -0.68% below the 52-week low of $1.47. If we look at the company’s 10-day average daily trading volume, we find that it stood at 3.74 million shares traded. The 3-month trading volume is 4.22 million shares.
The consensus among analysts is that Esperion Therapeutics Inc (ESPR) is Buy stock at the moment, with a recommendation rating of 1.62. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 2 out of 8 have rated it as a Hold, with 6 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.19.
Esperion Therapeutics Inc (NASDAQ:ESPR) trade information
Sporting -3.00% in the red today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the ESPR stock price touched $1.46 or saw a rise of 15.61%. Year-to-date, Esperion Therapeutics Inc shares have moved -33.86%, while the 5-day performance has seen it change -16.38%. Over the past 30 days, the shares of Esperion Therapeutics Inc (NASDAQ:ESPR) have changed -14.41%. Short interest in the company has seen 28.9 million shares shorted with days to cover at 7.27.
Wall Street analysts have a consensus price target for the stock at $8, which means that the shares’ value could jump 81.75% from the levels at last check today.. The projected low price target is $8.0 while the price target rests at a high of $8.0. In that case, then, we find that the latest price level in today’s session is -447.95% off the targeted high while a plunge would see the stock gain -447.95% from the levels at last check today..
Esperion Therapeutics Inc (ESPR) estimates and forecasts
The company’s shares have lost -11.28% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 4.87%.
6 analysts offering their estimates for the company have set an average revenue estimate of 54.97M for the current quarter. 6 have an estimated revenue figure of 61.74M for the next ending quarter. Year-ago sales stood 137.74M and 73.83M respectively for this quarter and the next, and analysts expect sales will shrink by -60.09% for the current quarter and 4.87% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 40.11% over the past 5 years.
ESPR Dividends
Esperion Therapeutics Inc is expected to release its next earnings report on 2025-Mar-03 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Esperion Therapeutics Inc (NASDAQ:ESPR)’s Major holders
Insiders own 1.00% of the company shares, while shares held by institutions stand at 65.72% with a share float percentage of 66.39%. Investors are also buoyed by the number of investors in a company, with Esperion Therapeutics Inc having a total of 228.0 institutions that hold shares in the company. The top two institutional holders are WASATCH ADVISORS LP with over 16.86 million shares worth more than $37.44 million. As of 2024-06-30, WASATCH ADVISORS LP held 8.9319% of shares outstanding.
The other major institutional holder is BLACKROCK INC., with the holding of over 13.98 million shares as of 2024-06-30. The firm’s total holdings are worth over $31.04 million and represent 7.4068% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are WASATCH FUNDS TRUST-Wasatch Ultra Growth Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . As of Dec 31, 2024 , the former fund manager holds about 3.37% shares in the company for having 6.68 shares of worth $9.71 million while later fund manager owns 6.18 shares of worth $8.99 million as of Dec 31, 2024 , which makes it owner of about 3.12% of company’s outstanding stock.
